Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia.

Abstract

INTRODUCTION:

Patients with hepatitis B early antigen (HBeAg)-negative chronic hepatitis B (CHB) and low-level viremia are a heterogeneous group. Identifying those at risk of developing active CHB requiring antiviral therapy is important. In this study, we prospectively characterize incidence rates and predictors of transitioning from inactive to active CHB in a North American adult cohort.

METHODS:

Participants in the multicenter National Institute of Diabetes and Digestive and Kidney Diseases Hepatitis B Research Network cohort who were HBeAg negative with baseline hepatitis B virus (HBV) DNA ≤ 10,000 IU/mL were included in the study. Cox regression models were used to estimate the proportion of individuals in 3 baseline HBV DNA categories (≤100, 101 to ≤2,000, and 2,001 to ≤10,000 IU/mL) who developed phase transition defined by HBV DNA > 10,000 IU/mL and alanine aminotransferase (ALT) > 2× upper limit of normal or initiated treatment during follow-up.

RESULTS:

Of 970 participants meeting inclusion criteria, 15% experienced phase transition or initiated treatment over a median follow-up of 4 years: 9% of those with baseline HBV DNA ≤ 100 IU/mL, 14% with HBV DNA 101 to ≤2,000 IU/mL, and 24% with HBV DNA 2,001 to ≤10,000 IU/mL (P < 0.001). The overall rate of phase transition or treatment initiation was 7.6 per 100 person-years: 4.6 in those with HBV DNA ≤ 100 IU/mL, 6.8 in those with HBV DNA 101 to ≤2,000 IU/mL, and 12.2 in those with HBV DNA 2,001 to ≤10,000 IU/mL (P < 0.001). Factors independently associated with higher rate of phase transition or treatment initiation included HBV genotype B or C, higher baseline ALT and HBV DNA levels, lower platelet count, quantitative hepatitis B surface antigen > 1,000 IU/mL, and hyperlipidemia. Only higher ALT, higher HBV DNA, and lower platelets were associated with phase transition when patients starting treatment were censored.

DISCUSSION:

Most adults in this North American cohort with HBeAg-negative CHB and low-level viremia remained inactive and off treatment over 4 years. Transition from inactive to active CHB is infrequent and predominantly associated with viral rather than host factors.

• Authors: Kali Zhou, Abdus S Wahed, Stewart Cooper, Adrian M Di Bisceglie, Robert J Fontana, Marc G Ghany, Mandana Khalili, Anna S Lok, Robert Perrillo, William M Lee, Daryl T Y Lau, Richard Sterling, Harry L A Janssen, Norah A Terrault
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 114 Issue 11 Pg. 1753-1763 (11 2019) ISSN: 1572-0241 [Electronic] United States
• PMID: 31658127 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• DNA, Viral
• Hepatitis B e Antigens

Topics

• Adult
• Antiviral Agents (therapeutic use)
• Carrier State (immunology)
• DNA, Viral (analysis)
• Female
• Hepatitis B (epidemiology, immunology, therapy, virology)
• Hepatitis B e Antigens (analysis)
• Hepatitis B virus (immunology, isolation & purification)
• Humans
• Liver Function Tests (methods, statistics & numerical data)
• Male
• Middle Aged
• North America (epidemiology)
• Patient Acuity
• Serologic Tests (methods, statistics & numerical data)
• Time-to-Treatment (standards)
• Viremia (diagnosis, epidemiology, etiology)